FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Ruff Shamim					<u>Sa</u>	2. Issuer Name and Ticker or Trading Symbol Sarepta Therapeutics, Inc. [SRPT]										tionship of Reporting all applicable) Director		ng Perso	on(s) to 10% C	
(Last) (First) (Middle) 215 FIRST STREET					3. Date of Earliest Transaction (Month/Day/Year) 11/08/2016										х	Officer (give title below) SVP, Regulato		y Affai	Other (specil below) Affairs & Qual	
SUITE 415					4. lf .	4. If Amendment, Date of Original Filed (Month/Day/Year)									Indiv ne)	Individual or Joint/Group Filing (Check Applicable e)				
(Street)															Х	Form	filed by One	e Report	ing Per	son
CAMBRIDGE MA 02142														Form filed by More than One Reporting Person						
(City)	(5	State)	(Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					if any	emed ion Date, /Day/Yea		3. Transaction Code (Instr. 8)		4. Securities Acquired (Disposed Of (D) (Instr. 3 and 5)					5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amoun	nt	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(1130.4)
Common Stock 11/08/20					2016	16			М		1,000		Α	\$26.24		21	21,239 ⁽¹⁾)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversior or Exercise Price of Derivative Security		ifany	emed ion Date, ı/Day/Year)	4. Transa Code (I 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amoun or			8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owr For Dire or li (I) (I 4)	nership m: ect (D) ndirect Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

\$26.24

1. Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding \$80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds \$100 million.

Date

1,000

Exercisable

(2)

V (A) (D)

Code

Μ

Expiration

01/02/2023

Date

2. 25% of the option became exercisable on the first anniversary of the date of hire (01/02/2013) and 1/48th of the total granted option becomes exercisable on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of hire.

Remarks:

Incentive Stock

Option

(right to buy)

> <u>/s/David Tyronne Howton, as</u> <u>Attorney-in-Fact for Shamim</u> <u>11/10/2016</u>

of

Shares

1,000

\$0.00

12,097

D

Title

omme

Stock

Ruff

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

11/08/2016

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.